Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.080
Sell
RSI(14)
36.119
Neutral
STOCH(KDJ)(9,3,3)
39.650
Sell
ATR(14)
0.252
High Vlolatility
CCI(14)
-154.189
Sell
Williams %R
72.308
Sell
TRIX(12,20)
-0.089
Sell
StochRSI(14)
0.000
Oversold
Search
Kamada Ltd
KMDAAdd to Watchlist
7.710USD
-0.315-3.93%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
444.72MMarket Cap
22.00P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Kamada Ltd
Currency: USD Updated: 2026-05-15Key Insights
Kamada Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 50 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kamada Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Kamada Ltd Highlights
StrengthsRisks
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.62% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 180.46M.
Fairly Valued
The company’s latest PE is 22.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.17M shares, decreasing 7.11% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 839.30K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
12.333
Target Price
+53.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Kamada Ltd is 9.60, ranking 1 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 44.68M, representing a year-over-year increase of 14.54%, while its net profit experienced a year-over-year increase of 6.46%.
Score
Financials
8.75
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.39
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
9.85
Kamada Ltd's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Kamada Ltd is 7.35, ranking 76 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 22.00, which is 245.83% below the recent high of 76.10 and 589.69% above the recent low of -107.76.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 50/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Kamada Ltd is 8.67, ranking 12 out of 155 in the Pharmaceuticals industry. The average price target is 13.00, with a high of 15.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
12.333
Target Price
+53.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Kamada Ltd
KMDA
3
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Kamada Ltd is 7.08, ranking 53 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 8.46 and the support level at 7.16, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
8.095
Sell
MA10
8.206
Sell
MA20
8.211
Sell
MA50
8.376
Sell
MA100
8.280
Sell
MA200
7.625
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Kamada Ltd is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 48.83%, representing a quarter-over-quarter decrease of 1.86%. The largest institutional shareholder is James Simons, holding a total of 762.95K shares, representing 1.32% of shares outstanding, with 5.90% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
First Israel Mezzanine Investors Ltd.
Gov Financial Holdings, Ltd.
Phoenix Investment and Finances Ltd
Recanati (Leon Yehuda)
Tsur (David)
Wells Fargo Advisors
Dimensional Fund Advisors, L.P.
Acadian Asset Management LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kamada Ltd is 4.17, ranking 91 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.88. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.86
VaR
+3.43%
240-Day Maximum Drawdown
+17.71%
240-Day Volatility
+37.81%
Return
Best Daily Return
60 days
+4.25%
120 days
+8.08%
5 years
+20.87%
Worst Daily Return
60 days
-6.76%
120 days
-6.76%
5 years
-9.83%
Sharpe Ratio
60 days
-1.48
120 days
+0.79
5 years
+0.36
Risk Assessment
Maximum Drawdown
240 days
+17.71%
3 years
+30.85%
5 years
+44.43%
Return-to-Drawdown Ratio
240 days
+0.66
3 years
+0.53
5 years
+0.18
Skewness
240 days
+0.52
3 years
+1.31
5 years
+1.03
Volatility
Realised Volatility
240 days
+37.81%
5 years
+41.76%
Standardised True Range
240 days
+2.99%
5 years
+2.49%
Downside Risk-Adjusted Return
120 days
+124.91%
240 days
+124.91%
Maximum Daily Upside Volatility
60 days
+30.11%
Maximum Daily Downside Volatility
60 days
+36.38%
Liquidity
Average Turnover Rate
60 days
+0.11%
120 days
+0.13%
5 years
--
Turnover Deviation
20 days
-37.31%
60 days
-24.12%
120 days
-10.94%
Peer Comparison
Pharmaceuticals
Kamada Ltd
KMDA
7.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
